Panagiotis D. Kottaridis
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.
Journal: British journal of haematology
Published: April 14, 2026
Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells.
Journal: British journal of haematology
Published: October 17, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Journal: Blood
Published: April 18, 2025
Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.
Journal: Bone marrow transplantation
Published: March 02, 2025
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial.
Journal: BMJ open
Published: January 08, 2025
The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas.
Journal: European journal of haematology
Published: July 31, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
Journal: Blood
Published: February 27, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 12, 2024
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Journal: Leukemia
Published: May 30, 2023
Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
Journal: Bone marrow transplantation
Published: December 17, 2021
Last Updated: 09/26/2026